Patents Examined by Nizal S. Chandrakumar
  • Patent number: 11951133
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: April 9, 2024
    Assignee: NURIX THERAPEUTICS, INC.
    Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
  • Patent number: 11951213
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Grant
    Filed: August 4, 2023
    Date of Patent: April 9, 2024
    Assignee: LABORATORIOS LEON FARMA SA
    Inventors: Philippe Perrin, Jose Luis Velada, Dominique Drouin
  • Patent number: 11945813
    Abstract: Disclosed herein are 5-Substituted 4-amino-1H-benzo[c][1,2,6]thiadiazine 2,2-dioxide compounds useful as sweet flavor modifiers. Also disclosed herein are ingestible compositions that include one or more of these compounds in combination with a natural or artificial sweetener.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: April 2, 2024
    Assignee: FIRMENICH INCORPORATED
    Inventors: Joseph R. Fotsing, Catherine Tachdjian, Guy Servant, Brett Weylan Ching, Timothy Davis
  • Patent number: 11944686
    Abstract: Disclosed are conjugate molecules formed from an active agent which is linked to a cannabinoid moiety through a specified linker having ester and amide end groups. The active agent can be a COX-2 inhibitor moiety, and the cannabinoid moiety can be a cannabidiol moiety. These conjugate molecules are contemplated to potentially be effective in the treatment of medical conditions.
    Type: Grant
    Filed: April 21, 2023
    Date of Patent: April 2, 2024
    Assignee: AKOS BIOSCIENCES, INC.
    Inventors: Paul M. Hershberger, Yinghui Liu, Kirk William Hering, James Bernard Kramer, Ramanathan S. Lalgudi
  • Patent number: 11931348
    Abstract: The present invention relates to compounds of Formula I, pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I increase significantly low density lipoprotein receptor and are useful for preventing and treating of elevated cholesterol.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: March 19, 2024
    Assignee: Montréal Heart Institute
    Inventors: Steve Poirier, Brent Richard Stranix, Gaétan Mayer
  • Patent number: 11925690
    Abstract: The invention provides for bifunctional molecules comprising an Rpn11 binding partner and a target protein binding partner. A bifunctional molecule according to the invention binds to Rpn11 and to the target protein, thereby facilitating degradation of the target protein bound to the target protein binding partner. The invention also provides for use of a bifunctional molecule for preventing or treating disease.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: March 12, 2024
    Assignee: AMPHISTA THERAPEUTICS LIMITED
    Inventors: Alessio Ciulli, Andrea Testa, Scott Hughes, Steven Peter Butcher
  • Patent number: 11926636
    Abstract: This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile(lorlatinib) maleate. The invention also relates to pharmaceutical compositions comprising lorlatinib maleate, and to methods of using lorlatinib maleate and compositions comprising it in the treatment of abnormal cell growth, such as cancer, in mammals.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: March 12, 2024
    Assignee: Pfizer Inc.
    Inventor: Klimentina Dimitrova Pencheva
  • Patent number: 11926633
    Abstract: The present disclosure relates to a JAK inhibitor upadacitinib intermediate and a preparation method therefor, and to a preparation method for a JAK inhibitor upadacitinib. The upadacitinib intermediate of the present application is as shown in Formula (II) or Formula (III), wherein, R is a protective group of nitrogen atoms, and R1 is an open-chain or cyclic amine group. Compared with the prior art, the method for the synthesis of upadacitinib of the present application, significantly reduces cost, is environmentally-friendly. And the quality of the final product is well controlled.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: March 12, 2024
    Assignee: SUZHOU PENGXU PHARMATECH CO., LTD
    Inventors: Peng Wang, Pixu Li, Qiang Wei, Wen Cheng, Hao Wu
  • Patent number: 11918571
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: March 5, 2024
    Assignee: Praxis Precision Medicines, Inc.
    Inventors: Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
  • Patent number: 11919877
    Abstract: The present invention enables provision of a production method for 1,2,3,5,6-pentathiepane, the method comprising, in the following order, step A for reacting a trithiocarbonate, sulfur, and a methane dihalide together using a phase-transfer catalyst in a multilayer system having a water layer and an organic layer, step B for separating the water layer from the organic layer, and step C for stopping the reaction using an acid.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: March 5, 2024
    Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventors: Hiroyuki Tanagi, Kouhei Takemura, Hiroshi Horikoshi
  • Patent number: 11918569
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: March 5, 2024
    Assignee: Poxel SA
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • Patent number: 11911401
    Abstract: Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
    Type: Grant
    Filed: January 6, 2022
    Date of Patent: February 27, 2024
    Assignee: TURTLE BEAR HOLDINGS, LLC
    Inventor: Paul Edward Stamets
  • Patent number: 11911375
    Abstract: A solid oral nicotine formulation is disclosed, the formulation comprises a nicotine-ion exchange resin combination, and a salt comprising inorganic divalent cations, wherein the salt has a water-solubility of at least 5 grams per 100 mL of water measured at 25 degrees Celsius, atmospheric pressure and pH 7.0.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: February 27, 2024
    Assignee: FERTIN PHARMA A/S
    Inventors: Kent Albin Nielsen, Jessie Poulsen
  • Patent number: 11912915
    Abstract: The present invention relates to a phosphine precursor for the preparation of a quantum dot, and a quantum dot prepared therefrom. Using the phosphine precursor for the preparation of a quantum dot of the present invention, a quantum dot with improved luminous efficiency and higher luminous color purity can be provided.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: February 27, 2024
    Assignee: SK Chemicals Co., Ltd.
    Inventors: Hee Il Chae, Jeong Ho Park, Kyung Sil Yoon, Ju-Sik Kang, Yu Mi Chang, Nam-Choul Yang, Jae Kyun Park, Song Lee
  • Patent number: 11897859
    Abstract: The coumarin compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.
    Type: Grant
    Filed: March 9, 2023
    Date of Patent: February 13, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Christophe Tratrat, Michelyne Haroun
  • Patent number: 11896670
    Abstract: A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt.
    Type: Grant
    Filed: August 23, 2022
    Date of Patent: February 13, 2024
    Assignee: Mind Medicine, Inc.
    Inventors: Daniel Trachsel, Matthias Emanuel Liechti, Felix Lustenberger
  • Patent number: 11897856
    Abstract: Synthesis of a compound N-(Naphthalen-1-ylcarbamothioyl)furan-2-carboxamide and its use as an insecticidal agent.
    Type: Grant
    Filed: October 12, 2023
    Date of Patent: February 13, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Mohamed A. Gad
  • Patent number: 11884640
    Abstract: The invention relates to processes for preparing benzoprostacyclin analogues and intermediates prepared from the process, and the benzoprostacyclin analogues prepared therefrom. The invention also relates to cyclopentenone intermediates in racemic or optically active form.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: January 30, 2024
    Assignee: CHIROGATE INTERNATIONAL INC.
    Inventors: Chun-Yu Lin, Tzyh-Mann Wei, Shih-Yi Wei
  • Patent number: 11883499
    Abstract: Disclosed are conjugate molecules formed from an active agent which is linked to a cannabinoid moiety through a specified linker having ester and amide end groups. The active agent can be a COX-2 inhibitor moiety, and the cannabinoid moiety can be a cannabidiol moiety. These conjugate molecules are contemplated to potentially be effective in the treatment of medical conditions.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: January 30, 2024
    Assignee: AKOS BIOSCIENCES, INC.
    Inventors: Paul M. Hershberger, Yinghui Liu, Kirk William Hering, James Bernard Kramer
  • Patent number: 11883399
    Abstract: The present disclosure describes pharmaceutical formulations of bromocriptine and method of manufacturing and using such formulations. The formulations are useful for treating physiological disorders including improving glycemic control in the treatment of type 2 diabetes. Also disclosed is synthesis of bromocriptine citrate, and compositions and dosage forms containing bromocriptine citrate.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: January 30, 2024
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta